Bispecific antibody affords complete post-exposure protection of mice from both Ebola (Zaire) and Sudan viruses

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Frei, Julia C ^a   Nyakatura, Elisabeth K ^a   Zak, Samantha E ^b   Bakken, Russell R ^b   Chandran, Kartik ^a   Dye, John M ^b   Lai, Jonathan R ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPECIFIC ANTIBODY; NEUTRALIZING ANTIBODY; PROTEIN BINDING; VIRUS ANTIBODY;

ANIMAL; ANTIBODY AFFINITY; CELL LINE; CHEMISTRY; CLASSIFICATION; CROSS REACTION; DISEASE MODEL; EBOLAVIRUS; HEMORRHAGIC FEVER, EBOLA; HUMAN; IMMUNOLOGY; MOUSE; POST EXPOSURE PROPHYLAXIS; PROTEIN ENGINEERING; SERODIAGNOSIS; VIROLOGY;

ANIMALS; ANTIBODIES, BISPECIFIC; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIBODY AFFINITY; CELL LINE; CROSS REACTIONS; DISEASE MODELS, ANIMAL; EBOLAVIRUS; HEMORRHAGIC FEVER, EBOLA; HUMANS; MICE; NEUTRALIZATION TESTS; POST-EXPOSURE PROPHYLAXIS; PROTEIN BINDING; PROTEIN ENGINEERING;

EID: 84955112946     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep19193     Document Type: Article

References (45)

1. Feldmann, H. & Geisbert, T. W. Ebola haemorrhagic fever. The Lancet 377, 849-862 (2011).
2. Kuhn, J. H. et al. Proposal for a revised taxonomy of the family Filoviridae: classification, names of taxa and viruses, and virus abbreviations. Archives of virology 155, 2083-2103 (2010).
3. Centers for Disease Control, Outbreaks Chronology: Ebolavirus Disease, 2015, Date accessed 11/28/2015, http://www.cdc.gov/vhf/ ebola/outbreaks/history/chronology.html
4. Baize, S. et al. Emergence of Zaire Ebola virus disease in Guinea. New England Journal of Medicine 371, 1418-1425 (2014).
5. Gire, S. K. et al. Genomic surveillance elucidates Ebola virus origin and transmission during the 2014 outbreak. Science (New York, NY) 345, 1369-1372, doi: 10.1126/science.1259657 (2014).
6. Park, D. J. et al. Ebola Virus Epidemiology, Transmission, and Evolution during Seven Months in Sierra Leone. Cell 161, 1516-1526, doi: 10.1016/j.cell.2015.06.007 (2015).
7. Agnandji, S. T. et al. Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe - Preliminary Report. The New England journal of medicine, doi: 10.1056/NEJMoa1502924 (2015).
8. Wong, G. & Kobinger, G. P. Backs against the wall: novel and existing strategies used during the 2014-2015 Ebola virus outbreak. Clinical microbiology reviews 28, 593-601, doi: 10.1128/cmr.00014-15 (2015).
9. Nyakatura, E. K., Frei, J. C. & Lai, J. R. Chemical and Structural Aspects of Ebola Virus Entry Inhibitors. ACS Infectious Diseases 1, 42-52, doi: 10.1021/id500025n (2015).
10. Dye, J. M. et al. Postexposure antibody prophylaxis protects nonhuman primates from filovirus disease. Proceedings of the National Academy of Sciences 109, 5034-5039 (2012).
11. Flyak, A. I. et al. Mechanism of human antibody-mediated neutralization of Marburg virus. Cell 160, 893-903, doi: 10.1016/j. cell.2015.01.031 (2015).
12. Murin, C. D. et al. Structures of protective antibodies reveal sites of vulnerability on Ebola virus. Proceedings of the National Academy of Sciences of the United States of America 111, 17182-17187, doi: 10.1073/pnas.1414164111 (2014).
13. Qiu, X. et al. Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature 514, 47-53, doi: 10.1038/ nature13777 (2014).
14. Chen, G. et al. Synthetic Antibodies with a Human Framework That Protect Mice from Lethal Sudan Ebolavirus Challenge. ACS Chemical Biology 9, 2263-2273, doi: 10.1021/cb5006454 (2014).
15. Dias, J. M. et al. A shared structural solution for neutralizing ebolaviruses. Nature structural & molecular biology 18, 1424-1427 (2011).
16. Pettitt, J. et al. Therapeutic intervention of Ebola virus infection in rhesus macaques with the MB-003 monoclonal antibody cocktail. Science translational medicine 5, 199ra113, doi: 10.1126/scitranslmed.3006608 (2013).
17. Qiu, X. et al. Sustained protection against Ebola virus infection following treatment of infected nonhuman primates with ZMAb. Scientific reports 3, 3365, doi: 10.1038/srep03365 (2013).
18. Fusco, M. L. et al. Protective mAbs and Cross-Reactive mAbs Raised by Immunization with Engineered Marburg Virus GPs. PLoS pathogens 11, e1005016, doi: 10.1371/journal.ppat.1005016 (2015).
19. Holtsberg, F. W. et al. Pan-ebolavirus and pan-filovirus mouse monoclonal antibodies: protection against Ebola and Sudan viruses. Journal of virology, doi: 10.1128/jvi.02171-15 (2015).
20. Hashiguchi, T. et al. Structural basis for Marburg virus neutralization by a cross-reactive human antibody. Cell 160, 904-912, doi: 10.1016/j.cell.2015.01.041 (2015).
21. Bale, S. et al. Structural Basis for Differential Neutralization of Ebolaviruses. Viruses 4, 447-470, doi: 10.3390/v4040447 (2012).
22. Lee, J. E. et al. Structure of the Ebola virus glycoprotein bound to an antibody from a human survivor. Nature 454, 177-182 (2008).
23. Lee, J. E. & Saphire, E. O. Ebolavirus glycoprotein structure and mechanism of entry. Future virology 4, 621-635 (2009).
24. Lee, J. E. & Saphire, E. O. Neutralizing ebolavirus: structural insights into the envelope glycoprotein and antibodies targeted against it. Current opinion in structural biology 19, 408-417 (2009).
25. Koellhoffer, J. F. et al. Crystal structure of the Marburg virus GP2 core domain in its postfusion conformation. Biochemistry 51, 7665-7675 (2012).
26. Malashkevich, V. N. et al. Core structure of the envelope glycoprotein GP2 from Ebola virus at 1.9- resolution. Proceedings of the National Academy of Sciences 96, 2662-2667 (1999).
27. Weissenhorn, W., Carf, A., Lee, K.-H., Skehel, J. J. & Wiley, D. C. Crystal structure of the Ebola virus membrane fusion subunit, GP2, from the envelope glycoprotein ectodomain. Molecular cell 2, 605-616 (1998).
28. Audet, J. et al. Molecular characterization of the monoclonal antibodies composing ZMAb: a protective cocktail against Ebola virus. Scientific reports 4, 6881, doi: 10.1038/srep06881 (2014).
29. Wilson, J. A. et al. Epitopes involved in antibody-mediated protection from Ebola virus. Science (New York, NY) 287, 1664-1666 (2000).
30. Bounds, C. E. et al. Human Polyclonal Antibodies Produced through DNA Vaccination of Transchromosomal Cattle Provide Mice with Post-Exposure Protection against Lethal Zaire and Sudan Ebolaviruses. PloS one 10, e0137786, doi: 10.1371/journal. pone.0137786 (2015).
31. Hernandez, H. et al. Development and Characterization of Broadly Cross-reactive Monoclonal Antibodies Against All Known Ebolavirus Species. The Journal of infectious diseases 212 Suppl 2, S410-413, doi: 10.1093/infdis/jiv209 (2015).
32. Wang, B. et al. Facile Discovery of a Diverse Panel of Anti-Ebola Virus Antibodies by Immune Repertoire Mining. Scientific reports 5, 13926, doi: 10.1038/srep13926 (2015).
33. Keck, Z. Y. et al. Macaque monoclonal antibodies targeting novel conserved epitopes within filovirus glycoprotein. Journal of virology, doi: 10.1128/jvi.02172-15 (2015).
34. Spiess, C., Zhai, Q. & Carter, P. J. Alternative molecular formats and therapeutic applications for bispecific antibodies. Molecular Immunology 67, 95-106, doi: http://dx.doi.org/10.1016/j.molimm.2015.01.003 (2015).
35. Maruyama, T. et al. Ebola virus can be effectively neutralized by antibody produced in natural human infection. Journal of virology 73, 6024-6030 (1999).
36. Parren, P. W., Geisbert, T. W., Maruyama, T., Jahrling, P. B. & Burton, D. R. Pre- and postexposure prophylaxis of Ebola virus infection in an animal model by passive transfer of a neutralizing human antibody. Journal of virology 76, 6408-6412 (2002).
37. Oswald, W. B. et al. Neutralizing antibody fails to impact the course of Ebola virus infection in monkeys. PLoS pathogens 3, e9, doi: 10.1371/journal.ppat.0030009 (2007).
38. Bale, S. et al. Structural basis for differential neutralization of ebolaviruses. Viruses 4, 447-470, doi: 10.3390/v4040447 (2012).
39. Koellhoffer, J. F. et al. Two synthetic antibodies that recognize and neutralize distinct proteolytic forms of the Ebola virus envelope glycoprotein. Chembiochem 13, 2549-2557 (2012).
40. Bray, M., Davis, K., Geisbert, T., Schmaljohn, C. & Huggins, J. A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever. The Journal of infectious diseases 178, 651-661 (1998).
41. Brannan, J. M. et al. Interferon alpha/beta Receptor-Deficient Mice as a Model for Ebola Virus Disease. The Journal of infectious diseases 212 Suppl 2, S282-294, doi: 10.1093/infdis/jiv215 (2015).
42. Brien, J. D. et al. Protection by Immunoglobulin Dual-Affinity Retargeting Antibodies against Dengue Virus. Journal of virology 87, 7747-7753, doi: 10.1128/jvi.00327-13 (2013).
43. Pace, C. S. et al. Bispecific antibodies directed to CD4 domain 2 and HIV envelope exhibit exceptional breadth and picomolar potency against HIV-1. Proceedings of the National Academy of Sciences of the United States of America 110, 13540-13545, doi: 10.1073/pnas.1304985110 (2013).
44. Mazor, Y., Barnea, I., Keydar, I. & Benhar, I. Antibody internalization studied using a novel IgG binding toxin fusion. Journal of immunological methods 321, 41-59, doi: 10.1016/j.jim.2007.01.008 (2007).
45. Wong, A. C., Sandesara, R. G., Mulherkar, N., Whelan, S. P. & Chandran, K. A Forward Genetic Strategy Reveals Destabilizing Mutations in the Ebolavirus Glycoprotein That Alter Its Protease Dependence during Cell Entry. Journal of virology 84, 163-175, doi: 10.1128/jvi.01832-09 (2010).